AMETEK

Ametek reported second-quarter sales growth of 15% year over year. It also announced the acquisition of Indicor's instrumentation business on May 6 for around $5 billion, its largest-ever acquisition, which is expected to close in the second half of 2026.

Why it matters: Acquisitions remain a top use of Ametek's funds. To grow inorganically at a consistent rate, Ametek needs to buy more small companies or raise its deal size each year. We like the Indicor acquisition because it adds complementary, highly engineered instrumentation to Ametek's portfolio. We do note, however, that Ametek took out significant debt (expecting 2.3 times gross debt to EBITDA) to pay a full price that we estimate represents around 16 times Indicor's operating income. Indicor is a good stress test for Ametek's acquisition strategy. If it digests well, we believe Ametek will likely source more deals in the multi-billion-dollar price range.

The bottom line: We maintain our $217 fair value estimate for wide-moat Ametek. We consider shares slightly overvalued. We think the market fully recognizes Ametek's ability to grow its topline nearly double digits for the next few decades. Ametek shares are rarely cheap because its organic plus inorganic growth algorithm is deeply instilled in the firm.

Between the lines: Ametek tends to raise the margins of acquired firms up to its own to help justify optically rich multiples, but Indicor already produces Ametek-level profitability. Ametek will have to rely on Indicor's strong organic growth to justify the purchase price. Optimistically, Indicor's decentralized brands operate in a few high-growth markets such as aerospace, healthcare, and electronics. CFO Dalip Puri said Ametek expects to deleverage at a pace of about 0.2 to 0.3 turns each quarter. We view this as logical and in line with Ametek's historically Exemplary capital allocation decision-making.

We assign wide-moat Ametek a $217 per share fair value estimate. We value the firm at around 27 times our 2026 adjusted earnings estimate. Ametek's wide moat, through which we believe it can outearn its cost of capital over the next 20 years, underpins its value.

Historically, Ametek’s revenue growth is split evenly between organic and inorganic sources. Acquisitions remain a keystone of Ametek's strategy, and we don't see this changing. We note that Ametek has raised its average deal size over time to grow at a consistent rate inorganically. We believe it can continue doing this for many years because its average deal size remains small and there is an abundance of targets that hold strong positions in niche, consolidated markets.

Organic growth should also remain robust; Ametek benefits from several secular trends, including the aging global population driving demand for medical devices, rising regulatory standards spurring demand for test-and-measurement instruments, and middle-class growth in developing nations expanding the global traveler cohort.

We expect near-term trends to aid in Ametek's growth. Aircraft manufacturers Boeing and Airbus have monstrous backlogs; the earliest delivery for a narrow-body plane ordered today is in the mid-2030s, forcing the existing commercial fleet to operate longer into its serviceable life. The aerospace aftermarket, in which Ametek has a strong presence, has experienced a rising demand.

Summing up the factors, we model Ametek to increase its top line in the high single digits, in line with management's target. The firm has a strong track record of improving margins at the business-unit level, and we don't expect this to change. Manufacturing and supply chain efficiencies, along with the implementation of digital tools, have contributed to more than 1,000 basis points of operating margin expansion over the past few decades. We expect Ametek to continue finding ways to improve operations and, as such, believe it can achieve low-teens EPS growth even without substantial share buybacks.

We assign Ametek a wide economic moat rating based on intangible assets and switching costs. On a normalized basis, the company has generated midteens returns on invested capital, inclusive of goodwill, over the past two decades. Notably, Ametek’s returns did not fall below its cost of capital during the global financial crises of 2001, 2009, and 2020. We think the company is more robust today, giving us confidence that Ametek will outearn its cost of capital over the next 20 years.

In recent decades, Ametek has strategically focused its portfolio on differentiated, precision-engineered products that give it a technological edge. The company works closely with customers during product development, raising research and development efficiency and giving Ametek an informational advantage over peers. As a result, Ametek tends to hold a leading share within its niche markets (typically around 30%) and has been able to pass rising input costs on to its customers each year.

Ametek's largest business segment, representing over two-thirds of revenue, is its electronic instruments group, or EIG. The segment houses a portfolio of analytical, testing, and measurement instruments, including spectrometers, sensors, balances, and monitors, sold to a diverse range of end markets. These products are incorporated into different phases of customer operations, including product development and design, quality control, and production. EIG generates operating margins in the high 20s, rivaling those of wide-moat peers such as Waters, Agilent, IDEX, Teradyne, and ITW.

EIG's products tend to represent a small percentage of the customer’s expense budget, but their failure can give rise to catastrophic outcomes. As such, the money saved by switching to a cheaper, less proven alternative is simply not worth the risk. For example, Ametek’s Navitar brand, founded in 1946, sells microscopy components used in the design and manufacturing of semiconductor chips and medical devices. Imperfections within these systems can lead to product failures and even human death. We think this dynamic shifts the customer’s focus away from price and toward factors such as performance and defect rate.

Customers become well-trained on EIG's instruments and the software commonly embedded within, which we think gives rise to additional switching costs. Moreover, many of Ametek’s products are specified in the design of the customer’s operations or products after passing rigorous regulatory hurdles. We believe this effectively locks Ametek in as a key supplier. As a result of strong switching costs, Ametek can benefit from higher-margin aftermarket sales, which we estimate represent around one-fourth of consolidated revenue.

We think intangible assets in the form of brand equity and technical superiority represent important factors in a customer’s purchase decision due to the mission-critical nature of Ametek’s products. An EIG subsidiary, Magnetrol, has roots tracing back to 1935. The subsidiary invented the first guided wave radar transmitter used for industrial liquid leveling. Today, it designs and manufactures level measurement and control devices installed into systems like nuclear power generators and pharmaceutical bioreactors. Magnetrol’s components have multidecade useful lives, and as a result, we suspect customers value the brand's time-tested performance and reputation for quality.

The same can be said for Ametek's aerospace and defense businesses, from which one fifth of consolidated revenue is derived and where higher-margin aftermarket revenue can easily span three decades. Commercial and military aircraft manufacturers tend to be extremely risk-averse because here, again, a malfunction can cause multi-billion-dollar losses or the loss of human life. Ametek's Taylor Hobson brand, established in 1886, sells surface profilers such as the autocollimator, used to measure small angular deviations in structural aircraft components like wings, landing gears, and engines. In our view, Ametek’s trusted relationships and technical edge built over many successful decades working with government customers represent formidable competitive advantages, especially amid rising regulations and global tensions.

Ametek’s other, smaller segment is its electromechanical group, or EMG. The segment is home to Ametek’s nonmeasurement products, such as pumps, heat exchangers, electrical connectors, specialty metals, and medical consumables. As with EIG, many EMG products hold dominant market share, perform mission-critical functions, and operate in harsh environments where reliability and performance cannot be compromised. We think the same moat sources, namely switching costs and intangible assets, are present in both segments. Although EMG generates slightly lower operating margins than EIG, it still exceeds those of industrial peers such as Parker-Hannifin and Emerson Electric.

Examples of rich brands within the segment include Rotron and Sealtron, founded in 1946 and 1953, respectively. Rotron manufactures a wide variety of aerospace blowers designed to withstand extreme vibration, temperature, electric current, salinity, moisture, and magnetic interference. Sealtron manufactures specialized hermetic connectors that enable signals to pass into sealed electronics enclosures within commercial planes, military jets, and satellites. Based on our understanding, the average Sealtron connector costs less than $100, but its failure can cause fires and electrical faults. We ultimately think this introduces switching costs and emphasizes Ametek's intangible assets, including rich intellectual property and brand strength.

We ultimately believe that Ametek's products are extremely difficult for third parties to replicate, and the small-TAM nature of its markets dissuades competitors from entering.

Ametek's pipeline of potential acquisitions is vast as the markets in which it operates are highly fragmented.

The firm has a well-established culture underpinned by highly autonomous business units that work closely with customers.

Ametek operates in markets with strong secular drivers acting as a tailwind for the company's products.

Ametek is overly reliant on acquisitions to grow. A shift in its M&A strategy poses an outsize risk.

The majority of Ametek's revenue is nonrecurring in nature, stemming mostly from the growth of customers' capital-expenditure budgets, which can be turned off rapidly.

Ametek's recent foray into the healthcare industry is risky, as unpredictable regulations can have a far-reaching impact on the success of the whole industry.